Overview of Lung Cancer :Perspectives from Cancer Genotype. Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center
|
|
- Shanon Greer
- 5 years ago
- Views:
Transcription
1 Overview of Lung Cancer :Perspectives from Cancer Genotype Ji-Youn Han, MD, PhD. Center for Lung Cancer National Cancer Center
2 Histologic classification of lung cancer
3 Therapeutic plateau reached with chemotherapy in NSCLC Platinum-based doublets (3 rd generation) Response rate 20-30% Median time to progression 3-4 months Median overall survival 8-10 months
4 Lung Cancer: high incidence & high mortality
5 주요암의 5 년생존율추이 : 전체
6 How many genes are altered in a typical solid tumor? ~10 Vogelstein 2010 AACR
7 EGFR as an anti-cancer target 1980s 1990s 1 st generation EGFR-TKIs Tumor type EGFR expression Head & neck cancer 80-95% NSCLC 40-80% Breast cancer 14-91% Colon cancer 25-77% Ovarian cancer 35-70% Pancreatic cancer 30-50%
8 Response rate, % Phase II results of gefitinib in previously treated advanced NSCLC (2002) 30 Vertical bars represent 95% CI mg 500 mg 250 mg 500 mg IDEAL 2 USA 3 rd -linesetting (n=216) IDEAL 1 Japan and Europe 2 nd or 3 rd line setting (n=210) Kris JAMA 2003;290:2149- Fukuoka JCO 2003;21:223
9 Japan & US approvals of Gefitinib Japan full approval granted July 2002 Indication: Inoperable or recurrent non small cell lung cancer. US accelerated approval granted May 2003: IRESSA is indicated as monotherapy for the treatment of patients with locally advanced or metastatic NSCLC after failure of both platinum-based and docetaxel chemotherapies. The effectiveness of IRESSA is based on objective response rates. There are no controlled trials demonstrating a clinical benefit, such as improvement in disease-related symptoms or increased survival. US Phase III for full regulatory approval (ISEL: OS superiority vs placebo)
10 Subpopulations & response to gefitinib in NSCLC Group Responses P Study Women vs. Men 19% vs. 3% IDEAL 2 1 Japanese vs. Caucasian Adenocarcinoma vs. Others Non-smoker vs. Former/current 28% vs. 10% IDEAL % vs. 4% IDEAL % vs. 8% <0.001 MSKCC 3 1 Fukuoka et al, JCO 2003; 2 Kris et al, JAMA 2003; 3 Miller et al, JCO 2004
11 Iressa Survival Evaluation Lung Cancer (ISEL) Previously treated (failure of 1 2 previous chemo-regimens) stage IIIB/IV NSCLC with PS 0 3 (n=1692) R Gefitinib 250mg/day (n=1129) Placebo (n=563) Primary endpoint: overall survival (OS) Secondary endpoints: progression-free survival (PFS), response rate (RR), safety, quality of life (QoL), duration of response Thatcher et al. Lancet 2005;366:1527
12 BR.21 Previously treated (failure of 1 2 previous chemo-regimens) stage IIIB/IV NSCLC with PS 0 3 (n=731) R 2 1 Erlotinib 150mg/day (n=488) Placebo (n=243) Primary endpoint: overall survival (OS) Secondary endpoints: progression-free survival (PFS), response rate (RR), safety, quality of life (QoL), duration of response Shepherd F, et al. N Engl J Med 2005;353:123 32
13 Phase III results of Gefitinib & Erlotinib in previously treated advanced NSCLC EGFR-TKI Trial Patients Survival ORR Gefitinib ISEL 1692 (HR=0.89 [95% CI: ]) 8% vs. 1% Erlotinib BR (HR=0.70 [95% CI: ]) 9% vs. 1% HR and 95% CI Favours active agent Favours placebo
14 Timeline of EGFR-targeting in NSCLC Iressa approval in Japan Final ISEL results shows no survival benefit with Iressa Iressa approval in US Tarceva approval in US AstraZeneca restricts Iressa use in US to those previously taking Iressa with demonstrated benefit
15 Why gefitinib failed in the United States? Sharma et al. Nature Reviews Cancer 2007; 7,
16 Survival & response rates by subgroup analysis (ISEL) Thatcher et al. Lancet 2005;366:1527
17 EGFR mutations in NSCLC (2004) Mutations associated with drug resistance Mutations associated with drug sensitivity Nat Rev Cancer 2007;7:16-181
18 Effects of EGFR-TK domain mutations on the ATP-binding cleft Wild type Mutant form Enhanced kinase activity Increased sensitivity to TKI Gazdar AF et al. Trends Mol Med 2004;10:481
19 EGFR mutations in NSCLC Somatic mutation in EGFR-TK domain More common in never- or light-smokers 30-40% of Asians 10-15% of Caucasians Oncogenic addiction Oncogenic in NIH3T3 cells & mice Exquisite sensitivity to EGFR-TKIs
20 Prospective non-randomized studies of NSCLC with EGFR mutations treated with EGFR-TKIs Author # screened EGFR mutations Agent RR (%) PFS (M) First-line Inoue Gefitinib Paz-Ares Erlotinib Tamura Gefitinib Asahina Gefitinib Sequist Gefitinib Kim Gefitinib Second-line Sutani Gefitinib First - & second or more-line Rosell (16.6%)-217Tx Erlotinib Kim et al. Lung Cancer 2010, Rosell et al. NEJM 2009;361:958
21 Iressa Pan-Asia Study (IPASS) Randomization period: March 2006 October 2007 Patients Chemo-naïve Age 18 years Adenocarcinoma Never or ex-light smokers Life expectancy 12 weeks WHO PS 0-2 Measurable stage IIIB / IV Gefitinib (250 mg / day) 1:1 randomization Carboplatin (AUC 5 or 6) / paclitaxel (200 mg / m 2 ) 3 weekly # ** Cross-over permitted End points Primary Progression-free survival (non-inferiority) Secondary Objective response rate Overall survival Quality of life Disease-related symptoms Safety and tolerability Exploratory Biomarkers EGFR mutation EGFR-gene-copy number EGFR protein expression Mok et al. NEJM 2009
22 Comparison of PFS by EGFR mutation status Mok et al. NEJM 2009
23 Phase III trials comparing gefitinib versus chemotherapy as first-line therapy in EGFR mutant NSCLC Study N TKI Chemo Primary endpoint NEJ002 G719X X19 L858R L861Q 198 Gefitinib TC PFS WJTOG3405 X19 L858R 172 Gefitinib DP PFS OPTIMAL X19 L858R 152 Erlotinib GC PFS EURTARC X19 L858R 146 Erlotinib Platinum +G or D PFS T: paclitaxel, C: carboplatin, G: gemcitabine, D: docetaxel, P: cisplatin
24 First-line EGFR-TKI vs. Chemo in EGFR mutant NSCLC NEJ002 (N=228) WJTOG3405 (N=172) OPTIMAL (N=165) EURTAC (n=174) Gefitinib PC Gefitinib DP Erlotinib GC Erlotinib Chemo (n=114) (n=114) (n=86) (n=86) (n=83) (n=82) (n=86) (n=88) ORR (%) P<.001 P<.0001 P<.0001 Median PFS (M) HR=0.30 HR=0.489 HR=0.16 HR=0.37 (95% CI: ) (95% CI: ) (95% CI: ) (05% CI: ) P<.001 P<.0001 P<.0001 P<.0001 Median OS (M)
25 Timeline of EGFR-targeting in NSCLC EGFR mutations identified in NSCLC 1990s Quinazoline EGFR Inhibitors discovered Erlotinib approved for NSCLC Gefitinib FDA approval was withdrawn Gefitinib approved for EGFR-M NSCLC EGFR mutation screening Gandi & Janne Clin Cancer Res 2012
26 Irreversible EGFR-TKIs: 2 nd generation EGFR-TKIs Agent Type EGFR IC 50 (nm) HER2 IC 50 (nm) Other targets Gefitinib Reversible NA Erlotinib Reversible NA Afatinib Irreversible HER-4 Neratinib Irreversible HER-4 Dacomitinib Irreversible 6 46 HER-4 Theoretical advantages of 2 nd -generation irreversible EGFR-TKIs Higher affinity for EGFR-TKI domain Irreversible TK blockade More complete EGFR signaling blockade by inhibiting HER2 or HER4 Modest in-vitro activity to T790M mutation Yun CH et al. PNAS 2008;105:2070 Suda K et al. JTO 2009; 4:1-4
27 Irreversible EGFR-TKIs in clinical trials HKI-272 (EGFR+HER2) XL647 (EGFR, HER2, VEGF) BIBW2992 (EGFR+HER2) PF (EGFR+HER2+HER4) RR 3% in TKI-resistant pts Intriguing response in G719X RR 2% in TKI-resistant pts (Sequist, JCO 2010) (Pennell, Chicago Lung 2008) RR 7% in TKI-resistant pts 2M PFS advantage (3.3 vs.1.1m) RR 7% in TKI-resistant pts (Miller, ESMO 2010) (Janne, ASCO 2009)
28 Afatinib in EGFR mutant NSCLC: LUX Lung-3
29 Response rate: Afatinib vs. PemCis
30 PFS: Afatinib vs. PemCis
31 Toxicity: Afatinib vs. PemCis Afatinib PemCis AE leading to discontinuation 23 (10%) 16 (14%) Drug-related AE leading to discontinuation 18 (8%) 13 (12%)
32 EML4-ALK fusion gene
33 Natural history of ALK-positive NSCLC 3-7% of NSCLC Adenocarcinoma : acinar, papillary, cribriform, mucin-producing, signet-ring cell Never or light smoking status Younger: median 51 years Minimal overlap with other oncogenic driver mutations Excess of hepatic mets & pleural/pericardial effusion at presentation
34 Diagnosis of ALK-rearranged NSCLC Fluorescence In Situ Hybridization (FISH) Camidge DR et al. Clin Cancer Res 2010;16: FISH characteristics Criteria for positivity Number of cells counted At least 50 cells % of positive signals > 15% Distance between 5 (green) & 3 (red) signals Greater than 2 signal diameter separation Presence of single 3 ALK signal only (single red) Yes Presence of single 5 ALK signal only (green only) No Ignatius Ou SH. 2011;5:471
35 Treatment of ALK-rearranged NSCLC ALK-TKI Sasaki T & Janne PA: Clin Cancer Res 2011;17:
36 Crizotinib
37 Crizotinib efficacy in ALK-rearranged NSCLC Efficacy A (n=119) PROFILE 1005 (n=136) ORR (CR+PR) [95% CI] 61% (2%+59%) [52-70%] 50% (1%+49%) [42-59%] Duration of response (range) 11.2 ( ) M 9.8 ( ) M Median PFS (95% CI) Median OS OS rate at 12M 10 M (8-15M) Not reached yet 81% Camidge DR, et al. J Clin Oncol 2011; 29 Suppl: Abstract 2501 Crino L et al. J Clin Oncol 2011;29 Suppl: abstract 7514
38 Crizotinib versus Chemotherapy in Advanced ALK-Positive Lung Cancer NEJM 2013
39 EGFR Timeline EGFR mutations identified in NSCLC 1990s Quinazoline EGFR Inhibitors discovered Erlotinib approved for NSCLC Gefitinib approved for NSCLC ALK Timeline Crizotinib developed Responses seen in ALK+NSCLC Treated on phase I study of crizotinib EML4-ALK discovered in NSCLC Crizotinib approved for ALK+-NSCLC Gandi & Janne Clin Cancer Res 2012
40 Cost of Cancer Drugs: What Price for What Benefit? Simple measures of efficacy could be based on the amount of time a new drug prolongs life. If survival is prolonged by more than 6 months and/or by more than onethird of the patient s life expectancy (eg, months or months), this would be considered extremely effective and would put the drug price in a higher range for example, over $50,000 per year, but not more than $75,000. A drug that prolongs survival by 3 to 6 months and/or by 25% to 33% of life expectancy (eg, months or months) would be considered beneficial and priced modestly perhaps between $30,000 to 50,000 per year. Finally drugs that demonstrate statistically significant survival benefits of 2 months or less and less than 25% prolongation of life expectancy would be considered to have minimal efficacy and priced below $30,000 a year.
41 2 nd generation ALK inhibitors in under investigation Crizotinib AP26113 LDK378 CH ALK IC 50 24nM 0.62nM 0.15nM 1.9nM Other targets C-Met EGFR T790M ROS-1 IGF1R - ORR (crizotinib-naïve) 60.8% (n=143) 50% (n=4) 60% (n=35) 93.5% (n=46) ORR (crizotinib-resistant) 75% (n=16) 57% (n=79) 2nd Generation ALK Inhibitors (NSCLC) Very Difficult to Beat Xalkori on Response Rate Penetration of the Blood Brain Barrier & Increased Potency Could Lead to Better Efficacy Xalkori should be beatable front-line, not on ORR but PFS.
42 Xalkori TM (Crizotinib) 성분함량 성상 흰색또는연한노란색의분말이든흰색 / 분홍색의경질캡슐 효능효과 ALK-positive locally advanced or metastatic NSCLC Based on response rate 작용기전 Selective ATP competitive RTK-inhibitor (ALK, c-met, RON) 허가 2011 년 12 월 29 일한국 : ALK- 양성국소진행성또는전이성비소세포폐암의치료
43 Crizotinib: Absorption Peak plasma time: median 4 to 6 hours (following a single dose of crizotinib) Steady state: within 15 days (repeated 250mg twice a day) Bioavailability: mean 43% (range: 32% to 66%) following a single dose The solubility of crizotinib decreases with increasing ph & its bioavailability may be reduced with coadministration with drugs that elevate gastric ph. XALKORI can be administered with or without food A high-fat meal reduced crizotinib AUC and C max by approximately 14%. Poorly penetrate blood-brain barrier
44 Crizotinib: common side effects ( 25%) Vision problems (62-64%) These problems usually happen within 2 weeks of starting XALKORI flashes of light blurred vision light hurting eyes new or increased floaters nausea (53-57%) diarrhea (43-49%) vomiting (40-45%) hands and feet swelling (28-38%) constipation (27-38%) Grade 3-4 adverse reactions in at least 4% of patients in both studies : ALT increased & neutropenia
45 Dose modification: hematologic toxicities CTCAE Grade XALKORI Dosing Grade 3 Withhold until recovery to Grade 2, then resume at the same dose schedule Grade 4 Withhold until recovery to Grade 2, then resume at 200 mg twice daily In case of recurrence, withhold until recovery to Grade 2, then resume at 250 mg once daily. Permanently discontinue in case of Grade 4 recurrence. Hematologic toxicities except lymphopenia (unless associated with clinical events, e.g., opportunistic infections)
46 Dose modification: non-hematologic toxicities CTCAE Grade Grade 3 or 4 ALT or AST elevation with Grade 1 total bilirubin (TB) XALKORI Dosing Withhold until recovery to Grade 1 or baseline, then resume at 200 mg twice daily a Grade 2, 3 or 4 ALT or AST elevation with concurrent Grade 2, 3 or 4 TB elevation (in the absence of cholestasis or hemolysis) Any Grade pneumonitis b Grade 3 QTc prolongation Grade 4 QTc prolongation Permanently discontinue Permanently discontinue Withhold until recovery to Grade 1, then resume at 200 mg twice daily a Permanently discontinue a In case of recurrence, withhold until recovery to Grade 1, then resume at 250 mg once daily. Permanently discontinue in case of further Grade 3 or 4 recurrence. b Not attributable to NSCLC progression, other pulmonary disease, infection, or radiation effect.
47 Complex renal cysts Crizotinib 치료받은환자중 8명 (1% 미만 ) 에서복합성신낭종이보고됨 [ 아시아인환자 6명 (2% 미만 )] 치료를시작한이후 2-8개월이내에보고 8명중 2명의환자에서진단당시옆구리통증 어떤환자에서도뇨분석이상이나, 신장애가보고되지는않았음 종양재평가시및옆구리통증이나타나는경우에신낭종에대한방사선촬영모니터링 ( 예. CT, MRI 등 ) 을수행해야함 신낭종으로진단된환자는신기능검사와영상검사를사용한모니터링을고려해야함
48 Case 1 (Female/57 세 ) NSCLC (ADC) stage IV: Dx 1) Gemcitabine+cisplatin X 2: PD 2) : PF (Crizotinib)
49 Baseline After C4: Lt renal cortical cyst
50 Left kidney subcapsular lesion (C6) Tract seeding after aspiration (C10) Liver cystic lesion (C6) Multiseptated cyst (C10)
51 Clizotinib C10 Hold Crizotinib Alimta C2
52 Clizotinib C10 Hold Crizotinib Alimta C6
53 Clizotinib C10 Hold Crizotinib Alimta C6
54 Xanthogranulomatous perinephritis
55 ROS1 1.7% (18/1,073) Younger Never-smoker Adenocarcinoma Asians Good response to crizotinib Bergethon K et al. JCO 2012;30:
56
57 Actionable targets in lung adenocarcinomas
58 Actionable targets in squamous cell lung cancer % unknown 100% unknown
59 Summary: 1 st line therapy Testing for EGFR mutation & ALK rearrangements is critical before initiating 1 st -line treatment in advanced NSCLC. Strive to ensure enough cellular material is collected during the initial biopsy for molecular analysis. Platinum-based chemotherapy is still the standard therapy for pan-negative NSCLC.
60
61 First-line treatment for pan-negative (EGFR/ALK/ROS1 negative) NSCLC Questions. What is your preferred non-protocol first-line regimen for patients with pan-negative lung adenocarcinoma? 1) Pemetrexed + Cisplatin (or Carboplatin) 2) Gemcitabine+ Cisplatin (or Carboplatin) 3) Platinum-based chemotherapy + Bevacizumab 4) Erlotinib
62 Pem/Cis vs Gem/Cis in 1 st line NSCLC: Survival by histology Nonsquamous histology Months Squamous histology The treatment-by-histology interaction analysis (P=0.001) Scagliotti, et al. J Clin Oncol 2008;26:3543 Months
63 Maintenance chemotherapy Question A patient with advanced lung adenocarcinoma receives 4 cycles of cisplatin/pemetrexed and has had a partial response on CT scan. He has tolerated therapy well but has a grade 1 peripheral neuropathy and grade 2 anemia. ECOG PS of 1 At this point, you would recommend: 1) 2 more cycles of cisplatin/pemetrexed 2) Continuation maintenance with single-agent pemetrexed 3) Switch maintenance with erlotinib 4) Switch maintenance with docetaxel 5) Observation with close follow-up, implementing second-line treatment upon progression
64 Continuous maintenance therapy with pemetrexed (PRAMOUNT) Therapy at PD 58% 58% (PEM 4%)
65 Switch maintenance therapy Trial Year induction Maintenance PFS OS (M) Therapy at progression Tx No Tx No Median P Median P SATURN 2010 Platinum -based X Erlotinib % 12.3 wk Placebo % (EGFR-TKI 16%) 12.0 < wk JMEN 2009 Platinum -based X PEM % 4.0 mo Placebo % (PEM 19%) 13.4 < mo Fidias 2009 GCb X Docetaxel 153 NR 5.7 mo 12.3 <.001 Observation 156 Docetaxel 63% 2.7 mo
66 Factors predicting benefit from maintenance chemotherapy Factors Response to 1 st -line therapy Examples JMEN: CR/PR-OS HR 0.81, SD-OS HR 0.68 SATURN: CR/PR-OS HR 0.94, SD-OS HR 0.72 PARAMOUNT: CR/PR-PFS HR 0.48 (95% CI, ), SD-PFS HR 0.74 (95% CI, ) PS ECOG PS of 0 or 1 Likelihood of therapy at PD Histology Molecular characteristics Fidias: OS was similar in immediate vs. delayed docetaxel SATURN: Adenocarcinoma-OS HR 0.77 (95% CI, ) SQCC-OS HR 0.86 (95% CI, ) JMEN: PFS & OS benefits were confined to nonsq histology The clinical benefit of EGFR-TKI was greatest in EGFR-mutant NSCLC. ATLAS trial: KRAS wild-pfs HR 0.67 ( ), KRAS mutant-pfs HR 0.93 ( )
67 AVAPERL PARAMOUNT PointBreak study
68 Continuous maintenance therapy Survival from maintenance randomization (ITT) PARAMOUT POINTBREAK AVAPERL PRONOUNCE PEM+CP PEM+CP PEM+CB+A Pac+CB+A PEM+CP+A PEM+CP+A PEM+CB PEM+CB+A Median PFS (M) PEM Placebo PEM+A A PEM+A A PEM PEM+A P < < Median OS (M) (maintenance group) 13.9 (16.9) 11.0 (14.0) 12.6 (17.7) 13.4 (15.7) P PEM, pemetrexed; CP, cisplatin; CB, carboplatin; A, Avastin (bevacizumab); Pac, paclitaxel; NR: not reached
69 Second-line treatment for pan-negative (EGFR/ALK/ROS1 negative) NSCLC Questions. What is your preferred non-protocol 2nd-line regimen for patients with pan-negative NSCLC? 1) EGFR-TKI 2) Chemotherapy
70 TAILOR Study Design Advanced/ recurrent Prior platinum -based doublet EGFR wild type KRAS wild type ECOG PS 0-2 R 1:1 Docetaxel 75 mg/m 2 IV d 1, 21 or 35 mg/m 2 IV d 1, 8, 15, 28 Erlotinib 150 mg oral daily CROSS- OVER NOT ALLOWED Stratification: Minimization approach Center Recurrent/progressive disease Prior chemotherapy regimen (pemetrexed vs. gemcitabine vs. vinorelbine) ECOG PS (0-1 vs. 2) Adequacy of tissue sample (optimal vs. suboptimal) Garassino MC, et al. J Clin Oncol. 2012;30. Abstract LBA7501.
71 TAILOR: PFS in Intent-to-Treat Group Docetaxel (n=94) Erlotinib (n=92) P CR 4.3% 0 PR 9.6% 2.2% SD 27.6% 20.6% PD 58.5% 77.2% RR (CR+PR) DCR (CR+PR+SD) 13.9% 2.2% % 22.8% Garassino MC, et al. J Clin Oncol. 2012;30. Abstract LBA7501.
72 DELTA: Docetaxel vs. Erlotinib Advanced NSCLC Prior 1-2 regimens ECOG PS 0-2 EGFR M test R 1:1 Docetaxel 60 mg/m 2 IV Q 3 wks Erlotinib 150 mg oral daily Stratification: Minimization approach Gender PS Histology Institution Okano et al ASCO.
73 DELTA: PFS in Intent-to-Treat Group Docetaxel (n=85) Erlotinib (n=106) P CR 0 0 PR 20.0% 5.6% SD 50.6% 47.2% PD 29.4% 47.2% RR (CR+PR) DCR (CR+PR+SD) 20.0% 5.6% % 70.6% 0.017
74 EGFR-wild type lung adenocarcinomas are heterogeneous!
75 Summary First-line EGFR-TKI Therapy & for patients with EGFR mutations Particular sensitive to EGFR-TKIs: higher RR & longer PFS Improved toxicity profile & QOL of EGFR-TKIs compared to chemotherapy 2 nd generation EGFR-TKI? Chemotherapy is better for EGFR wild type NSCLC in any setting EGFR wild type NSCLCs are not homogenous (ALK, ROS-1, RET, KRAS, etc) Test for other potentially actionable genetic alterations Both continuation & switch maintenance chemotherapy have demonstrated favorable toxicity profile, prolongation of PFS, & -in some instance, an OS benefit. There are still considerable controversies in maintenance therapy Economic consideration Additional toxicity with maintenance therapy In the absence of clear-cut survival advantage or differential improvement in symptoms, it may difficult to justify extending therapy instead of delaying.
76
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective
Management Guidelines and Targeted Therapies in Metastatic Non-Small Cell Lung Cancer: An Oncologist s Perspective Julie R. Brahmer, M.D. Associate Professor of Oncology The Sidney Kimmel Comprehensive
More informationMaintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute
Maintenance therapy in advanced non-small cell lung cancer. Egbert F. Smit MD PhD Dept Thoracic Oncology Netherlands Cancer Institute e.smit@nki.nl Evolution of front line therapy in NSCLC unselected pts
More informationPROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC. Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy
PROGNOSTIC AND PREDICTIVE BIOMARKERS IN NSCLC Federico Cappuzzo Istituto Toscano Tumori Ospedale Civile-Livorno Italy Prognostic versus predictive Prognostic: In presence of the biomarker patient outcome
More informationMaintenance paradigm in non-squamous NSCLC
Maintenance paradigm in non-squamous NSCLC L. Paz-Ares Hospital Universitario Virgen del Rocío Sevilla Agenda Theoretical basis The data The comparisons Agenda Theoretical basis The data The comparisons
More informationChoosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer
Choosing Optimal Therapy for Advanced Non-Squamous (NS) Non-Small Cell Lung Cancer Jyoti D. Patel, MD Associate Professor Feinberg School of Medicine Robert H Lurie Comprehensive Cancer Center Northwestern
More informationEGFR inhibitors in NSCLC
Suresh S. Ramalingam, MD Associate Professor Director of Medical Oncology Emory University i Winship Cancer Institute EGFR inhibitors in NSCLC Role in 2nd/3 rd line setting Role in first-line and maintenance
More informationMaintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse?
Maintenance Therapy for Advanced NSCLC: When, What, Why & What s Left After Post-Maintenance Relapse? Mark A. Socinski, MD Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive
More informationEGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS
EGFR MUTATIONS: EGFR PATHWAY AND SELECTION OF FIRST-LINE THERAPY WITH TYROSINE KINASE INHIBITORS Federico Cappuzzo Istituto Clinico Humanitas IRCCS Rozzano-Italy The EGFR/HER Family Ligand binding domain
More informationMAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf
MAINTENANCE TREATMENT CHEMO MAINTENANCE OR TARGETED OF BOTH? Martin Reck Department of Thoracic Oncology LungenClinic Grosshansdorf OUTLINE Background and Concept Switch Maintenance Continuation Maintenance
More informationSlide 1. Slide 2 Maintenance Therapy Options. Slide 3. Maintenance Therapy in the Management of Non-Small Cell Lung Cancer. Maintenance Chemotherapy
Slide 1 Maintenance Therapy in the Management of Non-Small Cell Lung Cancer Frances A Shepherd, MD FRCPC Scott Taylor Chair in Lung Cancer Research Princess Margaret Hospital, Professor of Medicine, University
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Data on first-line Overcoming T790M
More informationVirtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer.
Virtual Journal Club: Front-Line Therapy and Beyond Recent Perspectives on ALK-Positive Non-Small Cell Lung Cancer Reference Slides ALK Rearrangement in NSCLC ALK (anaplastic lymphoma kinase) is a receptor
More informationMaintenance Therapy for Advanced NSCLC: Which Patients, Which Approach?
Maintenance Therapy for Advanced NSCLC: Which Patients, Which Approach? Mark A. Socinski, MD Visiting Professor of Medicine and Thoracic Surgery Director, Lung Cancer Section, Division of Hematology/Oncology
More informationTreatment of EGFR mutant advanced NSCLC
Treatment of EGFR mutant advanced NSCLC Raffaele Califano Department of Medical Oncology The Christie and Manchester University Hospital Manchester, UK Outline Data on first-line Overcoming T790M mutation
More informationTargeted Agents as Maintenance Therapy. Karen Kelly, MD Professor of Medicine UC Davis Cancer Center
Targeted Agents as Maintenance Therapy Karen Kelly, MD Professor of Medicine UC Davis Cancer Center Disclosures Genentech Advisory Board Maintenance Therapy Defined Treatment Non-Progressing Patients Drug
More informationMolecular Targets in Lung Cancer
Molecular Targets in Lung Cancer Robert Ramirez, DO, FACP Thoracic and Neuroendocrine Oncology November 18 th, 2016 Disclosures Consulting and speaker fees for Ipsen Pharmaceuticals, AstraZeneca and Merck
More information1st line chemotherapy and contribution of targeted agents
ESMO PRECEPTORSHIP PROGRAMME NON-SM ALL-CELL LUNG CANCER 1st line chemotherapy and contribution of targeted agents Yi-Long Wu Guangdong Lung Cancer Institute Guangdong General Hospital Guangdong Academy
More informationDo You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement. Reference Slides Introduction
Do You Think Like the Experts? Refining the Management of Advanced NSCLC With ALK Rearrangement Reference Slides Introduction EML4-ALK Fusion Oncogene Key Driver in 3% to 7% NSCLC Inversion or Translocation
More information2 nd line Therapy and Beyond NSCLC. Alan Sandler, M.D. Oregon Health & Science University
2 nd line Therapy and Beyond NSCLC Alan Sandler, M.D. Oregon Health & Science University Treatment options for advanced or metastatic (stage IIIb/IV) NSCLC Suitable for chemotherapy Diagnosis Unsuitable/unwilling
More informationK-Ras signalling in NSCLC
Targeting the Ras-Raf-Mek-Erk pathway Egbert F. Smit MD PhD Dept. Pulmonary Diseases Vrije Universiteit VU Medical Centre Amsterdam, The Netherlands K-Ras signalling in NSCLC Sun et al. Nature Rev. Cancer
More informationExploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC)
Exploring Personalized Therapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) Suresh S. Ramalingam, MD Director of Thoracic Oncology Associate Professor Emory University Atlanta,
More informationImmune Checkpoint Inhibitors for Lung Cancer William N. William Jr.
Immune Checkpoint Inhibitors for Lung Cancer William N. William Jr. Diretor de Onco-Hematologia Hospital BP, A Beneficência Portuguesa Non-Small Cell Lung Cancer PD-1/PD-L1 Inhibitors in second-line therapy
More informationInhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS
Inhibidores de EGFR Noemi Reguart, MD, PhD Hospital Clínic Barcelona IDIPAPS Driver Mutations to Classify Lung Cancer Unknown 36% KRAS 25% EGFR 15% ALK 4% HER2 2% Double Mut 2% BRAF 2% PIK3CA
More informationAntiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab
Micro-ambiente tumorale. Antiangiogenici e immunoterapia: miti e realtà Milano, 11 Ottobre 2016 Antiangiogenici in combinazione a chemioterapia in prima linea: bevacizumab Francesco Grossi U.O.S. Tumori
More informationNSCLC: Terapia medica nella fase avanzata. Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza
NSCLC: Terapia medica nella fase avanzata Paolo Bidoli S.C. Oncologia Medica H S. Gerardo Monza First-line Second-line Third-line Not approved CT AND SILENT APPROVAL Docetaxel 1999 Paclitaxel Gemcitabine
More information1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC
1 st line chemotherapy and contribution of targeted agents in non-driver addicted NSCLC Dr Ross Soo, FRACP National University Cancer Institute, Singapore National University Health System Cancer Science
More informationASCO Highlights Lung Cancer
ASCO Highlights Lung Cancer Anne S. Tsao, M.D. Director, Mesothelioma Program Assistant Professor July 11, 2009 The University of Texas MD ANDERSON CANCER CENTER Department of Thoracic/Head & Neck Medical
More informationPersonalized Medicine for Advanced NSCLC in East Asia
Personalized Medicine for Advanced NSCLC in East Asia - Update treatment strategy for NSCLC based on Japanese clinical practice guideline - Masahiro Tsuboi, M.D., Ph.D. Associate-professor, School of Medicine,
More informationPractice changing studies in lung cancer 2017
1 Practice changing studies in lung cancer 2017 Rolf Stahel University Hospital of Zürich Cape Town, February 16, 2018 DISCLOSURE OF INTEREST Consultant or Advisory Role in the last two years I have received
More informationChanging demographics of smoking and its effects during therapy
Changing demographics of smoking and its effects during therapy Egbert F. Smit MD PhD. Dept. Pulmonary Diseases, Vrije Universiteit Medical Centre, Amsterdam, The Netherlands Smoking prevalence adults
More informationBiomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007
Biomarkers of Response to EGFR-TKIs EORTC-NCI-ASCO Meeting on Molecular Markers in Cancer November 17, 2007 Bruce E. Johnson, MD Dana-Farber Cancer Institute, Brigham and Women s Hospital, and Harvard
More information11/21/2009. Erlotinib in KRAS Mt patients. Bevacizumab in Squamous patients
Decision-Making in Non-Small Cell Lung Cancer (NSCLC): Moving from Empiric to Personalized & Molecular-based Therapy David R. Gandara, MD University of California Davis Cancer Center Disclosures Research
More informationLONDON CANCER NEW DRUGS GROUP RAPID REVIEW. Erlotinib for the third or fourth-line treatment of NSCLC January 2012
Disease background LONDON CANCER NEW DRUGS GROUP RAPID REVIEW Erlotinib for the third or fourth-line treatment of NSCLC January 2012 Lung cancer is the second most common cancer in the UK (after breast),
More informationLung Cancer Case. Since the patient was symptomatic, a targeted panel was sent. ALK FISH returned in 2 days and was positive.
Lung Cancer Case Jonathan Riess, M.D. M.S. Assistant Professor of Medicine University of California Davis School of Medicine UC Davis Comprehensive Cancer Center 63 year-old woman, never smoker, presents
More informationTreatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line
Treatment of EGFR-Mutation+ NSCLC in 1st- and 2nd-Line Martin Reck David F. Heigener Department of Thoracic Oncology Hospital Grosshansdorf Germany Identification of driver mutation in tumor specimens
More informationIRESSA (Gefitinib) The Journey. Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca
IRESSA (Gefitinib) The Journey Anne De Bock Portfolio Leader, Oncology/Infection European Regulatory Affairs AstraZeneca Overview The Drug The Biomarker and Clinical Trials Sampling Lessons Learned The
More informationManagement Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors
Management Strategies for Lung Cancer Sensitive or Resistant to EGRF Inhibitors Conor E. Steuer, MD Assistant Professor The Winship Cancer Institute of Emory University July 27, 2017 1 Lung Cancer One
More informationSao Paulo, Abril 2014
Tratamento de Manutencao e outros Sao Paulo, Abril 2014 Rogerio C. Lilenbaum, M.D. Professor of Medicine Yale Cancer Center Chief Medical Officer Smilow Cancer Hospital What Is Maintenance Therapy? Use
More informationEGFR Mutation-Positive Acquired Resistance: Dominance of T790M
Treatment of EGFR Mutation-Positive Acquired Resistance: T790M+ or T790M- H. Jack West, MD Swedish Cancer Institute, Seattle, WA EGFR Mutation-Positive Acquired Resistance: Dominance of T790M Yu, Clin
More informationMetastatic NSCLC: Expanding Role of Immunotherapy. Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian
Metastatic NSCLC: Expanding Role of Immunotherapy Evan W. Alley, MD, PhD Abramson Cancer Center at Penn Presbyterian Disclosures: No relevant disclosures Please note that some of the studies reported in
More informationPlotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma
Pieter E. Postmus University of Liverpool Liverpool, UK Plotting the course: optimizing treatment strategies in patients with advanced adenocarcinoma Disclosures Advisor Bristol-Myers Squibb AstraZeneca
More informationLudger Sellmann 1, Klaus Fenchel 2, Wolfram C. M. Dempke 3,4. Editorial
Editorial Improved overall survival following tyrosine kinase inhibitor treatment in advanced or metastatic non-small-cell lung cancer the Holy Grail in cancer treatment? Ludger Sellmann 1, Klaus Fenchel
More informationTargeted Therapies for Advanced NSCLC
Targeted Therapies for Advanced NSCLC Current Clinical Developments Friday, June 3, 2016 Supported by an independent educational grant from AstraZeneca Not an official event of the 2016 ASCO Annual Meeting
More informationAgenda. 6:30pm 7:00pm. Dinner. 7:00pm 7:15pm. NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice.
Agenda 6:30pm 7:00pm Dinner 7:00pm 7:15pm Welcome and Introductions Natasha Leighl, MD 7:15pm 7:50pm 7:50pm 8:00pm NSCLC Treatment in 2014: Focus on Use of 2nd Generation TKIs in Clinical Practice Questions
More informationLUNG CANCER. Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology. Best of ASCO, İstanbul
LUNG CANCER Başak Oyan-Uluç, MD Yeditepe University Hospital Medical Oncology Best of ASCO, İstanbul 2012 23.6.2012 Treatment of Metastatic NSCLC EGFR targetted treatments 1st line: EGFR-mutated: Afatinib
More informationMaintenance Treatment for Advanced NSCLC. Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017
Maintenance Treatment for Advanced NSCLC Yvonne Summers PhD, FRCP ESMO Preceptorship Programme March 2017 Milestones in the Palliative Systemic Treatment of NSCLC 1990 2000 2010 2015 Platinum based Chemotherapy
More informationSlide 1. Slide 2. Slide 3. Disclosures. Personalized Medicine for Advanced NSCLC in East Asia. No conflicts related to this presentation
Slide 1 12 th International Lung Cancer Conference Personalized Medicine for Advanced NSCLC in East Asia Masahiro Tsuboi, M.D., Ph.D. Group Chair, Lung Cancer Surgical Study Group in Japan Clinical Oncology
More informationTarget therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy)
Target therapy nel NSCLC con EGFR M+ Cesare Gridelli Division of Medical Oncology S.G. Moscati Hospital Avellino (Italy) cgridelli@libero.it First-Line Treatment of Advanced NSCLC EGFR-mutation analysis
More informationStrategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors
Strategies in the therapy of advanced NSCLC SAMO Winter-Conference 2008 on Chest tumors Miklos Pless Medical Oncology Kantonsspital Winterthur 2 Setting the stage. 1995: Chemotherapy works! Meta-Analysis
More informationJoachim Aerts Erasmus MC Rotterdam, Netherlands. Drawing the map: molecular characterization of NSCLC
Joachim Aerts Erasmus MC Rotterdam, Netherlands Drawing the map: molecular characterization of NSCLC Disclosures Honoraria for advisory board/consultancy/speakers fee Eli Lilly Roche Boehringer Ingelheim
More informationSequencing in EGFR-Mutated NSCLC: Does Order Matter?
Sequencing in EGFR-Mutated NSCLC: Does Order Matter? Maximilian J. Hochmair, MD Otto Wagner Hospital Vienna, Austria Disclosures Honoraria: AstraZeneca, AbbVie, Pfizer, Boehringer Ingelheim, Roche, MSD,
More informationTargeted therapies for advanced non-small cell lung cancer. Tom Stinchcombe Duke Cancer Insitute
Targeted therapies for advanced non-small cell lung cancer Tom Stinchcombe Duke Cancer Insitute Topics ALK rearranged NSCLC ROS1 rearranged NSCLC EGFR mutation: exon 19/exon 21 L858R and uncommon mutations
More informationThe Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance
The Rapidly Changing World of EGFR Mutation-Positive Acquired Resistance H. Jack West, MD Swedish Cancer Institute Seattle, WA GRACE Targeted Therapies Forum September 16, 2017 Cleveland, OH EGFR Mutation-Positive
More informationAntiangiogenic Agents in NSCLC Where are we? Which biomarkers? VEGF Is the Only Angiogenic Factor Present Throughout the Tumor Life Cycle
Antiangiogenic Agents in NSCLC Where are we? Which biomarkers? Martin Reck Department e t of Thoracic c Oncology ogy Hospital Grosshansdorf Germany VEGF Is the Only Angiogenic Factor Present Throughout
More informationChemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC)
Chemotherapy and Immunotherapy in Combination Non-Small Cell Lung Cancer (NSCLC) Jeffrey Crawford, MD George Barth Geller Professor for Research in Cancer Co-Program Leader, Solid Tumor Therapeutics Program
More informationComparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC)
J Lung Cancer 2009;8(2):61-66 Comparison of Gefitinib versus Docetaxel in Patients with Pre-Treated Non-Small Cell Lung Cancer (NSCLC) More effective treatments in first, second, and third-line of metastatic
More informationOpzioni terapeutiche nel paziente ALK-traslocato
Opzioni terapeutiche nel paziente ALK-traslocato Giulio Metro S.C. Oncologia Medica Ospedale Santa Maria della Misericordia, Azienda Ospedaliera di Perugia Carcinoma del polmone non microcitoma: quali
More informationTratamiento de la enfermedad avanzada en cáncer de pulmón
Tratamiento de la enfermedad avanzada en cáncer de pulmón S. Ponce Aix! S. Oncología Médica Hospital Universitario 12 de Octubre Madrid Survival by stage NSCLC Stage Distribution NSCLC Stage 5-year Survival
More information1st-line Chemotherapy for Advanced disease
SESSION 3: ADVANCED NSCLC 1st-line Chemotherapy for Advanced disease JY DOUILLARD MD PhD Professor Emeritus in Medical Oncology Chief Medical Officer (CMO) ESMO Lugano CH Percent Survival HISTORICAL BASIS
More informationALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer
ALK Inhibition: From Biology to Approved Therapy for Advanced Non-Small Cell Lung Cancer Dr. Ben Solomon Medical Oncologist, Thoracic Oncology Peter MacCallum Cancer Centre Melbourne, Australia Dr. D.
More information7/6/2015. Cancer Related Deaths: United States. Management of NSCLC TODAY. Emerging mutations as predictive biomarkers in lung cancer: Overview
Emerging mutations as predictive biomarkers in lung cancer: Overview Kirtee Raparia, MD Assistant Professor of Pathology Cancer Related Deaths: United States Men Lung and bronchus 28% Prostate 10% Colon
More informationImmune checkpoint blockade in lung cancer
Immune checkpoint blockade in lung cancer Raffaele Califano Department of Medical Oncology The Christie and University Hospital of South Manchester, Manchester, UK Outline Background Overview of the data
More informationImmunotherapy in the clinic. Lung Cancer. Marga Majem 20 octubre 2017
Immunotherapy in the clinic. Lung Cancer Marga Majem 20 octubre 2017 mmajem@santpau.cat Immunotherapy in the clinic. Lung Cancer Agenda Where we come from? Immunotherapy in Second line Immunotherapy in
More informationRecent Advances in Lung Cancer: Updates from ASCO 2017
Recent Advances in Lung Cancer: Updates from ASCO 2017 Charu Aggarwal, MD, MPH Assistant Professor of Medicine Division of Hematology-Oncology Abramson Cancer Center University of Pennsylvania 6/15/2017
More informationNivolumab: esperienze italiane nel carcinoma polmonare avanzato
NSCLC avanzato: quali novità nel 2018? Negrar, 30 Ottobre 2018 Nivolumab: esperienze italiane nel carcinoma polmonare avanzato Francesco Grossi UOC Oncologia Medica Fondazione IRCCS Ca Granda Ospedale
More informationQuale sequenza terapeutica nella malattia EGFR+
Trattamento della malattia avanzata oncogene-addicted Quale sequenza terapeutica nella malattia EGFR+ Chiara Bennati AUSL della Romagna Ravenna, Italy A matter of fact Outline Can we improve PFS/OS with
More informationThe Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer
The Evolving Role of Molecular Markers in Managing Non-Small Cell Lung Cancer Nathan A. Pennell, M.D., Ph.D. Assistant Professor Solid Tumor Oncology Cleveland Clinic Taussig Cancer Institute www.cancergrace.org
More informationSecond-line treatment for advanced NSCLC
Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY DISCLOSURE OF INTEREST Speaker Bureau: Eli Lilly, MSD, BI, BMS, Roche, AZ UNIVERSITY
More informationPersonalized maintenance therapy in advanced non-small cell lung cancer
China Lung Cancer Research Highlight Personalized maintenance therapy in advanced non-small cell lung cancer Kazuhiro Asami, Kyoichi Okishio, Tomoya Kawaguchi, Shinji Atagi Department of Clinical Oncology,
More informationFrequency of Epidermal Growth Factor Mutation Status and Its Effect on Outcome of Patients with Adenocarcinoma of the Lung
Journal of Cancer Therapy, 2014, 5, 1012-1020 Published Online September 2014 in SciRes. http://www.scirp.org/journal/jct http://dx.doi.org/10.4236/jct.2014.511106 Frequency of Epidermal Growth Factor
More informationLung Cancer Epidemiology. AJCC Staging 6 th edition
Surgery for stage IIIA NSCLC? Sometimes! Anne S. Tsao, M.D. Associate Professor Director, Mesothelioma Program Director, Thoracic Chemo-Radiation Program May 7, 2011 The University of Texas MD ANDERSON
More informationBeyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy
Beyond ALK and EGFR: Novel molecularly driven targeted therapies in NSCLC Federico Cappuzzo AUSL della Romagna, Ravenna, Italy Oncogenic drivers in NSCLC Certain tumours arise as a result of aberrant activation
More informationOptimum Sequencing of EGFR targeted therapy in NSCLC. Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey
Optimum Sequencing of EGFR targeted therapy in NSCLC Dr. Sema SEZGİN GÖKSU Akdeniz Univercity, Antalya, Turkey Lung cancer NSCLC SCLC adeno squamous EGFR ALK ROS1 BRAF HER2 KRAS EGFR Transl Lung Cancer
More informationIncorporating Immunotherapy into the treatment of NSCLC
Incorporating Immunotherapy into the treatment of NSCLC Suresh S. Ramalingam, MD Roberto C. Goizueta Chair for Cancer Research Assistant Dean for Cancer Research Deputy Director, Winship Cancer Institute
More informationEmerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC
Emerging Algorithm for Optimal Sequencing of EGFR TKIs in EGFR Mutation Positive NSCLC Keunchil Park, MD, PhD Samsung Medical Center, Sungkyunkwan University School of Medicine Faculty Disclosure Consulting
More informationSecond-line treatment for advanced NSCLC
UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Second-line treatment for advanced NSCLC Silvia Novello silvia.novello@unito.it UNIVERSITY OF TORINO DEPARTMENT OF ONCOLOGY Life was so simple back in 2008 Di
More informationD Ross Camidge, MD, PhD
i n t e r v i e w D Ross Camidge, MD, PhD Dr Camidge is Director of the Thoracic Oncology Clinical Program and Associate Director for Clinical Research at the University of Colorado Cancer Center in Aurora,
More informationPRACTICE GUIDELINE SERIES
ELLIS et al. PRACTICE GUIDELINE SERIES The role of the epidermal growth factor receptor tyrosine kinase inhibitors as therapy for advanced, metastatic, and recurrent nonsmall-cell lung cancer: a Canadian
More informationPage: 1 of 27. Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer
Last Review Status/Date: December 2014 Page: 1 of 27 Non-Small-Cell Lung Cancer Description Over half of patients with non-small-cell lung cancer (NSCLC) present with advanced and therefore incurable disease,
More informationEGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence
102 Journal of Cancer Research Updates, 2012, 1, 102-107 EGFR Tyrosine Kinase Inhibitors Prolong Overall Survival in EGFR Mutated Non-Small-Cell Lung Cancer Patients with Postsurgical Recurrence Kenichi
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Molecular Analysis for Targeted Therapy of Non-Small-Cell Lung Cancer Page 1 of 52 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Molecular Analysis for Targeted
More informationEGFR TKI sequencing: does order matter?
EGFR TKI sequencing: does order matter? Nicolas Girard Thorax Institut Curie-Montsouris, Paris, France In Switzerland, afatinib is approved as monotherapy for patients with non-small cell lung cancer (Stage
More informationII sessione. Immunoterapia oltre la prima linea. Alessandro Tuzi ASST Sette Laghi, Varese
II sessione Immunoterapia oltre la prima linea Alessandro Tuzi ASST Sette Laghi, Varese AGENDA Immunotherapy post-chemo ( true 2/3L ) Immunotherapy in oncogene addicted NSCLC (yes/no? when?) Immunotherapy
More informationMaintenance Treatment of Advanced NSCLC
Maintenance Treatment of Advanced NSCLC Giorgio V. Scagliotti University of Torino Department of Clinical & Biological Sciences giorgio.scagliotti@unito.it UNIVERSTY OF TORINO DEPT. OF OF Maintenance /Consolidation/Sequencing
More informationBest of ASCO 2014: Highlights in Metastatic Non-Small Cell Lung Cancer
Best of ASCO 2014: Highlights in Metastatic Non-Small Cell Lung Cancer Howard (Jack) West, M JackWestM@gmail.com @JackWestM Swedish Cancer Institute Seattle, WA Best of ASCO 2014 Seattle, WA Learning Objectives
More informationState of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD
State of the Art Treatment of Lung Cancer Ravi Salgia, MD, PhD Professor and Chair Arthur & Rosalie Kaplan Chair Medical Oncology and Therapeutics Research Nothing to disclose DISCLOSURE Objectives Lung
More informationBiomarkers in oncology drug development
Biomarkers in oncology drug development Andrew Stone Stone Biostatistics Ltd EFSPI Biomarkers and Subgroups June 2016 E: andrew@stonebiostatistics.com T: +44 (0) 7919 211836 W: stonebiostatistics.com available
More informationSquamous Cell Carcinoma Standard and Novel Targets.
Squamous Cell Carcinoma Standard and Novel Targets. Mohamed K. Mohamed, MD, PhD Director of Thoracic Oncology Cone Health Cancer Center Greensboro, NC 1 Mohamed Mohamed, MD, PhD Squamous Cell Carcinoma:
More informationCURRENT STANDARD OF CARE OF LUNG CANCER. Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff
CURRENT STANDARD OF CARE OF LUNG CANCER Maroun El-Khoury, MD Consultant Oncologist/Hematologist American Hospital Dubai President of Medical staff Biopsy: Establish Diagnosis, Determine Histologic Subtype,
More informationMedical Treatment of Advanced Lung Cancer
Medical Treatment of Advanced Lung Cancer Oncology for Scientists April 26, 2018 Edwin Yau, MD., Ph.D. Assistant Professor of Oncology Department of Medicine Department of Cancer Genetics and Genomics
More informationAngiogenesis and tumor growth
Anti-angiogenic agents: where we are? Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Angiogenesis and tumor growth Journal of experimental Medicine 1972; 133: 275-88 1 Angiogenesis
More informationKazuhisa TAKAHASHI, MD, PhD
Kazuhisa TAKAHASHI, MD, PhD Professor and Chairman, Division of Respiratory Medicine, Juntendo University Faculty of Medicine & Graduate School of Medicine Deputy Secretary and Educational Committee Member
More informationINNOVATION IN LUNG CANCER MANAGEMENT. Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy
INNOVATION IN LUNG CANCER MANAGEMENT Federico Cappuzzo Department of Oncology-Hematology, AUSL della Romagna, Ravenna, Italy FIRST-LINE THERAPY FOR METASTATIC NSCLC IN 216 Stratification for EGFR, ALK
More informationTargeted Therapy for NSCLC: EGFR and ALK Fadlo R. Khuri, MD
EGFR and ALK Fadlo R. Khuri, MD President, American University of Beirut Professor of Medicine July 26, 2018 A great year end! Targeted Therapy for NSCLC: Evolving Landscape of Lung Adenocarcinoma NSCLC
More informationTreatment of ALK Positive Advanced NSCLC Fiona Blackhall PhD FRCP Medical Oncologist Manchester, UK
Treatment of ALK Positive Advanced NSCLC Fiona Blackhall PhD FRCP Medical Oncologist Manchester, UK ESMO The Christie Preceptorship in Lung Cancer March 2017 2017 : Similar incidence in women & men ADC
More informationVEGF-Inhibitors in NSCLC. Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany
VEGF-Inhibitors in NSCLC Martin Reck Department of Thoracic Oncology Hospital Grosshansdorf Germany Conflicts of interest Advisory Board: AstraZeneca Bristol-Myers Squibb Daiichi Sankyo Eli Lilly Merck
More informationLung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD. Mount Carrigain 2/4/17
Lung Cancer Genetics: Common Mutations and How to Treat Them David J. Kwiatkowski, MD, PhD Mount Carrigain 2/4/17 Histology Adenocarcinoma: Mixed subtype, acinar, papillary, solid, micropapillary, lepidic
More informationCombined Modality Therapy State of the Art. Everett E. Vokes The University of Chicago
Combined Modality Therapy State of the Art Everett E. Vokes The University of Chicago What we Know Some patients are cured (20%) Induction and concurrent chemoradiotherapy are each superior to radiotherapy
More informationTargeted therapy in lung cancer : experience of NIO-RABAT
Targeted therapy in lung cancer : experience of NIO-RABAT I.ELGHISSASSI, H.ERRIHANI Medical oncology department, NIO- RABAT 02-05- 2012, FEZ In Morocco, lung cancer is the most common tumor among men At
More informationImmunotherapy for NSCLC: Current State of the Art and Future Directions. H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States
Immunotherapy for NSCLC: Current State of the Art and Future Directions H. Jack West, MD Swedish Cancer Institute Seattle, Washington, United States Which of the following statements regarding immunotherapy
More information